AstraZeneca looks to pen injector approval to turn Bydureon diabetes sales around

AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector delivers microspheres that house exenatide, which is slowly released for better glycemic control.

Bydureon, which AstraZeneca picked up in its acquisition of Bristol-Myers Squibb's ($BMY) diabetes business in February--and which BMS had acquired from Amylin in August 2012--collected an earlier FDA approval as an injection. But the troubled Bydureon took a fall from projections, ranked by analysts in April 2013 as one of the top 10 blockbuster duds in biopharma.

A new delivery system for the same formulation can make a big difference, and AstraZeneca is looking to turn that flop around in the form of a pen injector that could make the drug more patient-friendly and accessible.

"The Bydureon Pen is a manually operated, prefilled single-use pen injector," AstraZeneca spokesman Andrew Davis told FierceDrugDelivery in an email. "… The pen is supplied with one custom needle … specific to this delivery system. The dose is prepared by affixing the covered needle to the pen, twisting the knob to transfer the diluent via a bypass channel to the microsphere chamber, and then agitating the mixture to suspend the microspheres."

Bydureon is designed to deliver the GLP-1 agonist exenatide, which is slowly released from small microspheres throughout the week and can be taken any time of the day with or without meals, according to the company. Using a pen instead of a self-injection can make the process much simpler.

"This system eliminates the need for the patient to transfer the medication between a vial and syringe during the self-injection process," Davis wrote.

The pen should be available to patients in the U.S. later this year, the company said.

AstraZeneca also sells an immediate-release version of the GLP-1 agonist called Byetta, which is already available in a pen injector. Between the two treatments, the British-Swedish company is looking to turn its diabetes business into a market leader, though it lags behind Novo Nordisk's ($NVO) once-daily, pen-injected Victoza, according to a PMLive story this week.

AstraZeneca is looking to improve upon the delivery concept for Bydureon, gunning for approval of an autoinjector device next year and, in the longer game, developing a once-monthly version of the drug, chief medical officer Briggs Morrison told PMLive.

"We are pleased to receive approval for the Bydureon Pen which can provide a powerful reduction in blood glucose levels along with the potential benefit of weight loss, through a once-weekly dose in a prefilled device," Morrison said in a statement.

- here's the release
- and here's the PMLive story

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…